latest pharmaceutical industry news

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors in mice Several viruses have a natural ability to eliminate cancer; however translating them into treatments has proven difficult, partly due to the immune system tends to kill them before they can reach cancer cells. Researchers fr...

Bristol Myers' Experimental Psoriasis drug succeeds in late-stage study defeats rival Amgen's Otezla Bristol Myers' experimental psoriasis drug, deucravacitinib has outmarched Amgen's Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial in patients with moderate to severe plaque psoriasis. Deucravaci...

Cycle Pharmaceuticals Hauls In USD 25 Million In A Debt Financing Agreement  Cycle Pharmaceuticals, a biotech company focusing exclusively on rare diseases, announced a strategic financing agreement worth USD25 million credit facility with Deutsche Bank AG.  Headquartered in the UK, Cycle Pharmaceut...

MorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies MorphoSys and Incyte announced the US FDA approval under accelerated approval for their treatment Monjuvi in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymp...

AstraZeneca demonstrates positive early results from its trial evaluating COVID-19 vaccine-AZD1222 In a frenzied race to find a global cure for COVID-19, several pharma players are testing waters and presenting results from clinical studies evaluating their potential candidates. Not long after, Moderna, a U...

Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19.   Regeneron is running two trials simultaneously, one for prevention and other for treatment, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Phase III trial is studyi...

Bayer and Orion's Nubeqa gets FDA recommendations for Prostate Cancer The U.S. FDA has given its nod to Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa is a steroidal androgen receptor inhibitor (ARi), and its recommendation came afte...

ImmusanT upgrading the management ahead of phase 2 celiac vaccine trial ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo’s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer. The management is also boosted with new VPs in program management and clinical oper...